Moderna, Inc. (MRNA)
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Moderna (MRNA) concluded the recent trading session at $42.55, signifying a -3.45% move from its prior day's close.
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi and Pfizer, targeting ~$500m annual revenues by 2030, with a forward P/S of ~3x and P/E of ~7.5x. MRNA's growth depends on COVID/flu combo vaccine, intismeran cancer program, and RSV vaccine, but faces higher risk due to elevated spending and lack of major partners.
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Moderna (MRNA) closed the most recent trading day at $47.99, moving 1.48% from the previous trading session.
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
Moderna rises after five-year phase IIb data show the combo of intismeran autogene plus Keytruda cuts recurrence or death risk by 49% in high-risk melanoma.
What's Happening With Moderna Stock?
Moderna stock surged 16% yesterday after receiving promising clinical trial results for its experimental skin cancer vaccine. The firm is working on mRNA-1893/V940, a personalized cancer vaccine developed in collaboration with Merck, which yielded encouraging outcomes in minimizing melanoma recurrence when paired with Keytruda immunotherapy.
Moderna Stock Is Surging. Why a Cancer Vaccine Study Has Sparked a Rally.
Wall Street is hopeful that a pipeline of cancer drugs can drive earnings growth as the respiratory vaccine business flounders.
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?
In a blast from the past, COVID-19 vaccine developer Moderna NASDAQ: MRNA just made headlines in 2026. Shares jumped up more than 17% on Jan. 13, Moderna's largest single-day up-move in over three years.
Moderna, Merck's skin cancer vaccine shows sustained benefit after five years
Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in combination with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial.
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?
MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
Moderna (MRNA) closed the most recent trading day at $40.6, moving +2.52% from the previous trading session.
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
